Still DiseaseAURAL-STILLNCT05055882
Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
An observational study of Still Disease, run by Hospices Civils de Lyon at 16 sites in France.
Trial summary
Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, evanescent rash and arthritis. Read more about this study
- Who is it for?
- Ages 3 years and older
- Conditions the study is for
- Still Disease
- What is being tested?
- children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
- How many people
- 400 participants
- Where
- 16 sitesFrance
- Study dates
- 1 Feb 2020to Dec 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Who may be able to join
- children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Who cannot join
- Not applicable
Trial locations and contacts
16 sites in 1 country.
16 sites in 1 country
France16 sites, 16 recruiting
- Recruiting
Centre Hospitalier d'Annecy
Annecy, 74370
Alice Bérezné, Dr, +33450636363, alice.bérezné@chu-annecy.fr
- Recruiting
Centre Hospitalier de Bourg en Bresse
Bourg-en-Bresse, 01012
Pascal Sève, +33426732636, pascal.seve@ch-lyon.fr
- Recruiting
Centre Hospitalier Bourgoin Jallieu
Bourgoin, 38300
Marielle Roux, Dr, +33469157329, marielle.roux@ch-bourgoin-jallieux.fr
- Recruiting
Centre Hospitalier de Châlon sur Saône
Châlon Sur Saône, 71321
Eric Monard, Dr, +33385446688, eric.monard@ch-chalon-sur-saone.fr
- Recruiting
Centre Hospitalier de Chambéry
Chambéry, 73000
Emmanuel Forestier, Dr, +33473965050, emmanuel.forestier@ch-chambery.fr
- Recruiting
Centre Hospitalier Alpes-Léman (CHAL)
Contamine-sur-Arve, 74130
Jason Hubac, Dr, +33450823022, Jason.hubac@chal.fr
- Recruiting
Centre Hospitalier du puy en velay
Le Puy-en-Velay, 43000
Julie Planchette, Dr, +33471043463, julie.planchette@ch-lepuy.fr
- Recruiting
Centre Hospitalier de Limoges
Limoges, 87000
Eric Liozon, Dr, +33555056990, eric.liozon@chu-limoges.fr
- Recruiting
Hôpital de la Croix Rousse
Lyon, Auvergne-Rhône-Alpes, 69004
Yvan Jamilloux, Dr, +33426732636, yvan.jamilloux@chu-lyon.fr
- Recruiting
Hopital Saint Luc Saint Joseph
Lyon, 69007
Stéphane Martinon, Dr, +33478618329, smartinon@ch-stjoseph-stluc.fr
- Recruiting
Hospices Civils de Lyon - Edouard Herriot
Lyon, 69008
Arnaud Hot, +33472117565, arnaud.hot@chu-lyon.fr
- Recruiting
Centre Hospitalier de Montélimar
Montélimar, 26200
Ahmed Azzedine, Dr, +33475534429, ahmed.azzedine@ch-montelimar.fr
- Recruiting
Centre Hospitalier de Valence
Valence, Drome, 26953
Thierry Zenone, Dr, +33475757274, Thierry.zenone@chu-valence.fr
- Recruiting
Centre Hospitalier Vienne
Vienne, 38200
Leopold Adelaide, Dr, +33474313355, leopold.adelaide@ch-vienne.fr
- Recruiting
Centre Hospitalier de Villefranche
Villefranche-sur-Saône, 69400
Julie Le Scanff, Dr, +33474092929, julie.le-scanff@ch-nordouest.fr
- Recruiting
Médipôle de Villeurbanne
Villeurbanne, 69100
Bertrand Issartel, Dr, +33472823400, Bertrand.issartel@medipole.fr
About this study
Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, evanescent rash and arthritis. Although it is benign in the vast majority of cases, life-threatening complications can occur. By definition, the disease affects adults over 16 years of age, however most experts now agree that the adult form and the pediatric form belong to a pathological continuum: Still's disease. In the absence of a specific biomarker, the diagnosis is still based on clinical and biological criteria, after the exclusion of differential diagnoses.
Classically, three evolutionary profiles of Adult-Onset Still's disease are individualized, depending on the evolution of symptoms over time:
Read more
- a monocyclic systemic form (30% of cases) characterized by clear systemic symptoms and in the foreground compared to the articular signs. This form evolves over several weeks to several months (on average 9 months), without exceeding a year. By definition, there is no recurrence;
- a polycyclic systemic form (30% of cases) defined by the occurrence of at least two systemic or joint episodes, separated by clinical remission intervals greater than two months, or even several years. The symptoms of relapses are not always the same as the initial symptoms. The number and severity of relapses is unpredictable and varies widely from patient to patient, but symptoms tend to become less severe over time.
- a chronic form, with predominant joint involvement (40%), resembling seronegative rheumatoid arthritis. Systemic signs are present during the first outbreaks of the disease. Subsequently, rheumatoid arthritis evolves on its own and one can see joint destruction or conversely ankylosing developments such as the classic bilateral, non-erosive fusing carpitis.
There are reasons to believe that the evolving profile of patients has changed since the emergence and generalization of biotherapies. Furthermore, no prognostic factor for the progression of Adult-Onset Still's disease has been found so far. The differences between pediatric and adult forms need to be confirmed and becoming pediatric forms in adulthood is poorly described.
The objective of this study is to set up a regional research database (Auvergne-Rhône-Alpes-Limousin) in order to describe the characteristics, treatment and evolution of patients with Still's disease.
- Conditions
- Still Disease
- Being tested
- children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
- Medical subject headings
- Arthritis, Juvenile
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospitalOther
Comparison of Adult-Onset Still's disease phenotypes
| Study group | Role | What they receive |
|---|---|---|
| children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital | children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital Receives: Other: children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital |
What is being measured
The primary outcome is the main question the study is designed to answer.
validation of classification criteria
number of participants with clinical and biological abnormalities, as assessed in the Yamaguchi and Fautrel criteria
Measured: at inclusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Sep 2021
- Study start1 Feb 2020
- Primary completionFeb 2025 (estimated)
- Study completionDec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Still DiseaseStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05055882
- Sponsor's protocol ID
- CRC_GHN_2021_003
- Acronym
- AURAL-STILL
- Status last verified
- Apr 2024
- First submitted
- 8 Sep 2021
- Last updated
- 26 Apr 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The individual participant data will not be shared
Study at a glance
From the registry record, last updated by the sponsor on 26 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Auvergne-Rhône-Alpes-Limousin Research Database for Still's Diseases in Children and Adults
- ClinicalTrials.gov ID
- NCT05055882
- Acronym / sponsor ID
- AURAL-STILL / CRC_GHN_2021_003
- Conditions
- Still Disease
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 1 Feb 2020 (actual)
- Primary completion
- Feb 2025 (estimated)
- Study completion
- Dec 2025 (estimated)
- First posted
- 24 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adult-Onset Still's disease is a polygenic autoinflammatory disease of unknown etiology. The autoinflammatory character individualizes it from autoimmune autoantibody diseases. Clinically, it results in the classic triad associating hectic fever, evanescent rash and arthritis. Although it is benign in the vast majority of cases, life-threatening complications can occur. By definition, the disease affects adults over 16 years of age, however most experts now agree that the adult form and the pediatric form belong to a pathological continuum: Still's disease. In the absence of a specific biomarker, the diagnosis is still based on clinical and biological criteria, after the exclusion of differential diagnoses.
Classically, three evolutionary profiles of Adult-Onset Still's disease are individualized, depending on the evolution of symptoms over time:
- a monocyclic systemic form (30% of cases) characterized by clear systemic symptoms and in the foreground compared to the articular signs. This form evolves over several weeks to several months (on average 9 months), without exceeding a year. By definition, there is no recurrence;
- a polycyclic systemic form (30% of cases) defined by the occurrence of at least two systemic or joint episodes, separated by clinical remission intervals greater than two months, or even several years. The symptoms of relapses are not always the same as the initial symptoms. The number and severity of relapses is unpredictable and varies widely from patient to patient, but symptoms tend to become less severe over time.
- a chronic form, with predominant joint involvement (40%), resembling seronegative rheumatoid arthritis. Systemic signs are present during the first outbreaks of the disease. Subsequently, rheumatoid arthritis evolves on its own and one can see joint destruction or conversely ankylosing developments such as the classic bilateral, non-erosive fusing carpitis.
There are reasons to believe that the evolving profile of patients has changed since the emergence and generalization of biotherapies. Furthermore, no prognostic factor for the progression of Adult-Onset Still's disease has been found so far. The differences between pediatric and adult forms need to be confirmed and becoming pediatric forms in adulthood is poorly described.
The objective of this study is to set up a regional research database (Auvergne-Rhône-Alpes-Limousin) in order to describe the characteristics, treatment and evolution of patients with Still's disease.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital | – | Other: children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospitalchildren and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital |
Who may qualify
- Ages
- 3 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Key inclusion criteria (1 listed)
- children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Key exclusion criteria (1 listed)
- Not applicable
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospitalComparison of Adult-Onset Still's disease phenotypes | Other | children and adult diagnosed with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital |
Primary outcome
validation of classification criteria
Time frame: at inclusion
number of participants with clinical and biological abnormalities, as assessed in the Yamaguchi and Fautrel criteria
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Apr 2024.
- Individual participant dataSharing planned: No. The individual participant data will not be shared
Related trials for Still Disease
RecruitingObservational study
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis
Not yet recruitingObservational study
Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.
Hemophagocytic Lymphohistiocytosis (HLH), Macrophage Activation Syndrome (MAS)
RecruitingObservational study
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Still's Disease, Adult-Onset, Systemic Inflammation
Not yet recruitingObservational study
Pulmonary Involvement in Children With Systemic JIA
Systemic Juvenile Idiopathic Arthritis, Lung Diseases
RecruitingPhase 2
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Juvenile Idiopathic Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
16 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Still Disease, run by Hospices Civils de Lyon at 16 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 16 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Yvan Jamilloux, Dr (+33426732636, yvan.jamilloux@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
validation of classification criteria (time frame: at inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2024.